172@29@17@143!~!172@29@0@53!~!|news|business|reporters-take-more-problems-for-lupin-as-usfda-cautions-company-4817051.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
FREE virtual training session on Passive Income Secrets: October 24 and 25, 2020, 10am to 1pm. Register Now!
you are here: HomeNewsBusiness
Last Updated : Feb 06, 2020 03:14 PM IST | Source: Moneycontrol.com

Reporter's Take | More problems for Lupin as USFDA cautions company

Moneycontrol's Shraddha Sharma gets in conversation with Viswanath Pilla to find out the impact of the USFDA warning on the company.

India's third largest drug-maker Lupin said on Monday that the USFDA has cautioned the company over its Tarapur manufacturing facility, which could come under regulatory action.

In a filing, Lupin said that it had received a communication from the US regulator on an inspection conducted at its manufacturing facility between September 16 and 20 as Official Action Indicated.

In this edition of Reporter’s Take, Moneycontrol's Shraddha Sharma gets in conversation with Viswanath Pilla to find how this development could impact the country.

Close
Watch the video for more.
First Published on Jan 14, 2020 09:42 pm
Sections